Observational studyCritical care (London, England)2016
Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study.
Observational study in Critical care (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02180906 (Biomarkers in Necrotizing Soft Tissue Infections - Aspects of the Innate Immune Response), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Biomarkers in Necrotizing Soft Tissue Infections - Aspects of the Innate Immune Response
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pentraxin-3 as a predictive marker of mortality in sepsis: an updated systematic review and meta-analysis.Critical care (London, England) · 2022Pooled it
- Discriminatory plasma biomarkers predict specific clinical phenotypes of necrotizing soft-tissue infections.The Journal of clinical investigation · 2021Trial
- Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial.Intensive care medicine · 2017Trial
- A validated model for early prediction of group A streptococcal aetiology in necrotising soft tissue infections using minimal patient data.BMC medicine · 2026Article
- Early identification and diagnosis of fournier gangrene: a machine learning approach integrating serological characterization.BMC infectious diseases · 2025Article
- Article
- The intricate pathogenicity of Group AVirulence · 2024Review
- Pentraxin-3 and Other Inflammatory Markers for an Infected Diabetic Foot Ulcer Diagnosis: A Prospective Study.Diagnostics (Basel, Switzerland) · 2023Article
- Clinical Characteristics and Histopathology in Suspected Necrotizing Soft Tissue Infections.Open forum infectious diseases · 2022Article
- Increase in the Complement Activation Product C4d and the Terminal Complement Complex sC5b-9 Is Associated with Disease Severity and a Fatal Outcome in Necrotizing Soft-Tissue Infection.Journal of innate immunity · 2022Article
- Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection.BMC infectious diseases · 2021Article
- Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections-A Prospective Observational Study.Frontiers in immunology · 2020Observational
- The roles of early surgery and comorbid conditions on outcomes of severe necrotizing soft-tissue infections.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2019Article
- SuPAR correlates with mortality and clinical severity in patients with necrotizing soft-tissue infections: results from a prospective, observational cohort study.Scientific reports · 2019Article
- The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis.Frontiers in immunology · 2019Review
- Combined Biomarkers Predict Acute Mortality Among Critically Ill Patients With Suspected Sepsis.Critical care medicine · 2018Article
- Associations of Plasma Nitrite, L-Arginine and Asymmetric Dimethylarginine With Morbidity and Mortality in Patients With Necrotizing Soft Tissue Infections.Shock (Augusta, Ga.) · 2018Observational
- Pentraxin-3, procalcitonin and lactate as prognostic markers in patients with sepsis and septic shock.Oncotarget · 2018Article
- Biomarker-guided antibiotic therapy-strengths and limitations.Annals of translational medicine · 2017Review
- Association between cytokine response, the LRINEC score and outcome in patients with necrotising soft tissue infection: a multicentre, prospective study.Scientific reports · 2017Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew biomarkers are needed to assess the severity of necrotizing soft tissue infection (NSTI) at an early stage and to individualize treatment strategies. We assessed pentraxin-3 (PTX3) as a marker of disease severity and risk of death in patients with NSTI.
methodsWe conducted a prospective, observational study in the intensive care unit at Copenhagen University Hospital, where treatment of NSTI is centralized at a national level. We compared PTX3, procalcitonin and C-reactive protein in septic shock versus nonshock patients and in amputated versus nonamputated patients using the Mann-Whitney U test. The prognostic value of the markers for 180-day mortality was assessed using Cox regression analyses.
resultsPatients with NSTI (n = 135) were included over 25 months with up to 2.5-year follow-up; 71% had septic shock, amputation was undertaken in 20% and the 180-day mortality was 27%. Baseline plasma PTX3 level was significantly higher in patients with septic shock (67.3 versus 24.6 ng/mL, p < 0.0001) and in patients who underwent amputation (118.6 versus 43.6 ng/mL, p = 0.019). No significant differences in baseline procalcitonin or C-reactive protein levels were found according to amputation (25.2 versus 7.0 μg/L, p = 0.060 and 202 versus 225 mg/L, p = 0.123), respectively. Baseline PTX3 level above the median was associated with death (p = 0.009, log-rank test) and the univariate Cox regression analysis revealed a significant association between PTX3 level upon admission and 180-day mortality (hazard ratio 2.60 (95% confidence interval 1.28-5.29), p = 0.008). When adjusted for age, sex, chronic disease and Simplified Acute Physiology Score II, no significant association was found.
conclusionsHigh PTX3 level is associated with septic shock, amputation and risk of death in patients with NSTI, but it is not an independent predictor of 180-day mortality in this patient group.
trial registrationClinicalTrials.gov Identifier: NCT02180906. Date of registration: June 29, 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.